Ayr Wellness (CSE: AYR.a) is set to report their fourth quarter and year end financials before market open on March 11th. Analysts have a consensus C$54.60 12-month price target on the company, via a total of four analysts, with one analyst having a strong buy rating and the other three have buy ratings. The street high comes from Beacon Securities with a C$76 price target, and the lowest target comes from PI Financial with a C$60 price target.
Three analysts have revenue estimates for the fourth quarter. The mean between all three is U$48.57 million; this number has been revised upwards from U$47.13 million at the start of the year.
For the full year, the average estimate between three analysts is currently U$155.77 million. This number has stayed flat since the start of the year.
Onto EBITDA estimates, there are currently three analysts who have fourth-quarter EBITDA estimates. The mean is currently U$20.45 million, with this number being revised upwards from U$19.63 million at the start of the year.
For the full-year the current EBITDA means across three analysts is U$57.2 million, with that number basically staying flat year-to-date.
Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
